Safety Profile
Information not yet available for this ingredient profile.
Interactions
Information not yet available for this ingredient profile.
Evidence and Scientific Findings
Ingredient Overview
Bamboo extract standardised for organic silica (typically 70%) is used for hair, skin, nail, and connective tissue support. It has an excellent safety record. Silica from food and plant sources is very well tolerated. No significant drug interactions at standard supplemental doses. High purity standardised bamboo silica has better bioavailability and tolerability than crystalline silica forms. Generally safe for long-term use at label doses.
Biological and Chemical Classification
- Scientific Name
- Bambusa vulgaris
Mechanism of Action
Information not yet available for this ingredient profile.
Clinical Evidence of Effectiveness
Information not yet available for this ingredient profile.
Pharmacokinetics
Information not yet available for this ingredient profile.
Recommended Dosage
Information not yet available for this ingredient profile.
SETI — Scientific Evidence Transparency Index
Executive Summary — Ingredient Assessment
- 10 studies reviewed
- 0 high-quality studies (meta-analysis or RCT)
- Main clinical benefit observed: Botanical
- Evidence consistency: High consistency across studies (100%)
- No significant safety signals identified in the reviewed literature.
The available scientific evidence for Bamboo Extract indicates notable safety signals that warrant caution. Use should be considered carefully and monitored, particularly in sensitive populations or alongside other medications.
Total SETI Score
High risk| Evidence quality | 10/40 |
| Evidence consistency | 20/20 |
| Safety signals | 0/20 |
| Study recency | 10/10 |
| Evidence transparency | 10/10 |
Evidence Summary
- 10 studies reviewed
- 0 high-quality studies (meta-analysis or systematic review)
- 0 studies identified benefits or no safety concern (GREEN)
- 10 studies reported limited or advisory safety evidence (YELLOW)
Evidence Policy
Only peer-reviewed scientific literature indexed in PubMed or comparable databases is included in this evaluation. Commercial websites, blogs, and marketing materials are excluded. All references include direct traceable links to source documents.
Last updated: 06 აპრ 2026, 12:09
Evidence Distribution
-
Observational / other LOW evidence YELLOWProtective effects of Bambusa vulgaris leaves extract on high-fat diet-induced MASLD: insights from in silico and in vivo study. ↗Sarkar S et al.. Protective effects of Bambusa vulgaris leaves extract on high-fat diet-induced MASLD: insights from in silico and in vivo study.. 3 Biotech. 2026. PMID:41727251.PMID 41727251 ↗Journal 3 BiotechYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41727251/
-
Observational / other LOW evidence YELLOWSpecies-driven variability in soil health and carbon storage across bamboo plantations. ↗Yasin G et al.. Species-driven variability in soil health and carbon storage across bamboo plantations.. Environ Monit Assess. 2026. PMID:41642381.PMID 41642381 ↗Journal Environ Monit AssessYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41642381/
-
Observational / other LOW evidence YELLOWEvaluation of NTD-O2, a Ghanaian herbal medicine, for onchocerciasis and animal African trypanosomiasis. ↗Anibea BZ et al.. Evaluation of NTD-O2, a Ghanaian herbal medicine, for onchocerciasis and animal African trypanosomiasis.. BMC Complement Med Ther. 2025. PMID:41361885.PMID 41361885 ↗Journal BMC Complement Med TherYear 2025Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41361885/
-
Observational / other LOW evidence YELLOWInvestigation of the Flexural and Tensile Properties of Hybrid Polyester Composites Reinforced with Bamboo Fibers and Red Mud Waste. ↗Dos Santos AJG et al.. Investigation of the Flexural and Tensile Properties of Hybrid Polyester Composites Reinforced with Bamboo Fibers and Red Mud Waste.. Polymers (Basel). 2025. PMID:40284325.PMID 40284325 ↗Journal Polymers (Basel)Year 2025Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/40284325/
-
Observational / other LOW evidence YELLOWComparison of Phytolith Characteristics of Three Bamboo Species' Cotyledon Organs. ↗Luo G et al.. Comparison of Phytolith Characteristics of Three Bamboo Species' Cotyledon Organs.. Plants (Basel). 2025. PMID:40284062.PMID 40284062 ↗Journal Plants (Basel)Year 2025Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/40284062/
-
Observational / other LOW evidence YELLOWAbelmoschus Mallow and Bambusa Vulgaris Fiber, Ipomoea Batatas Vegetable Waste Filler: Cellulose Extraction and Compatibility with PLA Bio Composites. ↗Keerthiveettil Ramakrishnan S et al.. Abelmoschus Mallow and Bambusa Vulgaris Fiber, Ipomoea Batatas Vegetable Waste Filler: Cellulose Extraction and Compatibility with PLA Bio Composites.. Int J Biol Macromol. 2025. PMID:39988152.PMID 39988152 ↗Journal Int J Biol MacromolYear 2025Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/39988152/
-
Observational / other LOW evidence YELLOWImpact of Bambusa vulgaris-supplemented diet on Nile tilapia challenged with Pseudomonas putida: Hematological, immune, and oxidative responses. ↗Fouad AM et al.. Impact of Bambusa vulgaris-supplemented diet on Nile tilapia challenged with Pseudomonas putida: Hematological, immune, and oxidative responses.. Fish Shellfish Immunol. 2025. PMID:39732380.PMID 39732380 ↗Journal Fish Shellfish ImmunolYear 2025Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/39732380/
-
Observational / other LOW evidence YELLOWBambusa vulgaris leaf extract inhibits the inflammatory and oxidative pathways in streptozotocin-induced diabetic rats. ↗Aladenika YV et al.. Bambusa vulgaris leaf extract inhibits the inflammatory and oxidative pathways in streptozotocin-induced diabetic rats.. J Ethnopharmacol. 2025. PMID:39580128.PMID 39580128 ↗Journal J EthnopharmacolYear 2025Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/39580128/
-
Observational / other LOW evidence YELLOWGenomic and Phenotypic Characterization of Streptomyces sirii sp. nov., Amicetin-Producing Actinobacteria Isolated from Bamboo Rhizospheric Soil. ↗Zakalyukina YV et al.. Genomic and Phenotypic Characterization of Streptomyces sirii sp. nov., Amicetin-Producing Actinobacteria Isolated from Bamboo Rhizospheric Soil.. Microorganisms. 2024. PMID:39770830.PMID 39770830 ↗Journal MicroorganismsYear 2024Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/39770830/
-
Observational / other LOW evidence YELLOWQuantitative ethnobotany of plants used for vernacular building construction in Ghana. ↗Boakye MK. Quantitative ethnobotany of plants used for vernacular building construction in Ghana.. PLoS One. 2024. PMID:39546476.PMID 39546476 ↗Journal PLoS OneYear 2024Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/39546476/
Score Transparency
0 of 10 approved references (score saturates at 10). More peer-reviewed studies = stronger evidence base.
Method: Q = number of approved references ÷ 10 (capped at 1.0)
Limited — mostly case reports or animal studies
Method: L = mean study-level weight across approved references. Level 1 (meta-analysis / systematic review) = 1.0; Level 2 (RCT) = 0.8; Level 3 (cohort/case-control) = 0.6; Level 4 (case report) = 0.4; Level 5 (animal / in-vitro) = 0.2.
Mixed or neutral — roughly equal benefit and risk signals
Method: D = (sum of risk-scored references − sum of benefit-scored references) ÷ total evidence score, then scaled from [−1, 1] to [0, 1]. 0.0 = pure benefit; 0.5 = neutral; 1.0 = pure risk.
One or more monitoring-level safety signals active
Method: S = 0.5 (neutral baseline) + sum of active signal severity deltas ÷ 10. Severity deltas: Critical = +2.0, High = +1.5, Moderate = +1.0, Low = +0.5. Capped at 1.0.
Final GIRI Score for Bamboo Extract. Risk level thresholds: Low 0–3.0 · Moderate 3.0–5.5 · High 5.5–7.5 · Critical 7.5–10.
Full methodology & data sources
The GIRI Score is computed entirely from structured data — no editorial scoring or subjective weighting is applied at any step.
- References: Only approved references are counted. Each reference is assigned an evidence level (L1–L5) and a direction (risk / neutral / benefit) by the reference manager or AI classifier.
- Safety Signals: Sourced from regulatory agencies (FDA, EMA, Health Canada, TGA, and others) and pharmacovigilance databases. Only active signals count toward the score.
- Formula version: GIRI Score v3.7.0 — Q × L × D × S × 10.
- Limitations: The score reflects published evidence and recorded signals as of the last update date. It is not a clinical risk assessment and should not replace advice from a qualified healthcare professional.
Risk Level Classification
Based on available regulatory signals and scientific evidence, this ingredient presents a low safety concern under normal conditions of use.
0–3.0
3.0–5.5
5.5–7.5
7.5–10
The score pin shows exactly where this ingredient falls on the fixed risk scale.
What drove the Low classification for Bamboo Extract
A score of 1.0 places this ingredient in the Low band. Thresholds: Low 0–3.0 · Moderate 3.0–5.5 · High 5.5–7.5 · Critical 7.5–10.
0 approved references.
Limited — mostly case reports or animal studies (Level 4–5).
Neutral or mixed — benefit and risk signals roughly balanced.
No active signals — S component is at neutral baseline (0.5), contributing no extra risk weight.
No major regulatory restrictions or advisories recorded across monitored jurisdictions (FDA, EMA, Health Canada, TGA, and others).
How are the Low / Moderate / High / Critical thresholds defined?
The four risk levels are fixed score bands. A score is assigned to exactly one level based on where it falls:
| Level | Score | Meaning |
|---|---|---|
| LOW | 0.0 – 2.9 | Sparse or predominantly beneficial evidence. No active safety alerts. |
| MODERATE | 3.0 – 5.4 | Mixed signals — some risk alongside benefit. Caution at high doses or in sensitive groups. |
| HIGH | 5.5 – 7.4 | Multiple studies or regulatory alerts documenting adverse effects. Professional oversight recommended. |
| CRITICAL | 7.5 – 10 | Regulatory restrictions in one or more major jurisdictions. Serious documented harm. Avoid without specialist supervision. |
Thresholds are fixed constants (GIRI_Score_Utils::LEVEL_THRESHOLDS). They do not change per ingredient and are never subject to editorial adjustment.